CommercialCoverageMedium impact
08.01.73g, Filgrastim (Neupogen®) and Related Biosimilars, and tbo-filgrastim (Granix®)
Independence Blue Cross·Oncology, Hematology, Internal Medicine +1 more·Pharmacy
Effective date
Jan 1, 2025
We identified it
Jun 19, 2026
Summary
The commercial policy for Filgrastim (Neupogen®), related biosimilars, and tbo-filgrastim (Granix®) has been updated effective January 1, 2025. This affects pharmacy-related billing for these white blood cell growth factor medications commonly used in oncology and other specialties.
Action Required
Immediately: Review the updated policy details at the provided URL to understand specific changes to coverage, prior authorization, or billing requirements for Filgrastim (Neupogen®), biosimilars, and tbo-filgrastim (Granix®). Update billing procedures and staff training accordingly for commercial plan claims involving these medications.